SeqLL Inc. (NASDAQ: SQL; SQLLW) announced the formation of a Scientific Advisory Board (SAB) on March 21, 2022, to enhance the development of its True Single Molecule Sequencing (tSMS®) technology. This board comprises esteemed leaders from the scientific community who will provide insights to expand SeqLL's reach in various omics fields. The SAB members include Claes Wahlestedt, M.D., Ph.D., and Efrat Shema, Ph.D., among others, known for their significant contributions to genomics and epigenetics. Their expertise is expected to strengthen SeqLL's collaborative partnerships and innovation in genomic medicine.
SeqLL Inc. (NASDAQ:SQL; SQLLW) has successfully closed the sale of an additional 189,000 shares of common stock at $4.24 each, raising approximately $801,360. This comes after the company’s initial public offering (IPO) concluded on August 31, 2021, with total gross proceeds now reaching around $13,810,950. Maxim Group LLC managed the offering, and further details can be found in the prospectus filed with the SEC. SeqLL aims to use its True Single Molecule Sequencing technology to enhance research in various omics fields.
SeqLL Inc. (NASDAQ: SQL) announced a peer-reviewed study demonstrating the efficacy of its tSMS® platform in identifying RNA signatures for diagnosing Coronary Artery Disease (CAD). Conducted by a team at George Washington University, the research found that traditional angiography may miss significant CAD cases. The new method, which sequences millions of RNA strands, offers insights into CAD biomarkers and may outperform existing clinical models. This innovation could transform healthcare by providing non-invasive diagnostic options.
SeqLL Inc. (NASDAQ: SQL) announced the publication of a novel microscopy-based epitranscriptomic method, developed in collaboration with Bernstein Laboratory, in the August issue of Cell Report Methods. This method utilizes SeqLL's exclusive tSMS technology to quantify epigenetically modified mRNA at single-cell resolution, enabling better cancer diagnosis and cellular analysis. The research was funded by NIH and highlights the potential of the tSMS platform in various scientific applications beyond initial cancer studies, offering insights into complex biological pathways.